Substituted urea depsipeptide analogs as activators of the clpp endopeptidase
US-2016200770-A1 · Jul 14, 2016 · US
Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase
US10676510B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10676510-B2 |
| Application number | US-201815863673-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 5, 2018 |
| Priority date | Aug 30, 2013 |
| Publication date | Jun 9, 2020 |
| Grant date | Jun 9, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the C1pP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for the treatment of a bacterial infection in a mammal, the method comprising the step of administering to the mammal a therapeutically effective amount of a compound having a structure represented by a formula: wherein R 3 and R 4 are covalently bonded, together with the intermediate atoms, comprise a piperazinyl ring substituted with methyl group; wherein each of R 60a , R 60b , R 60c , R 60d , and R 60e is independently selected from hydrogen, —F, —Cl, and methyl, provided that no more than three of R 60a , R 60b , R 60c , R 60d , and R 60e are not hydrogen; and wherein R 70a is methyl, or a pharmaceutically acceptable salt thereof, thereby treating the bacterial infection in the mammal. 2. The method of claim 1 , wherein the mammal is a human. 3. The method of claim 2 , wherein the human has been diagnosed with a bacterial infection. 4. The method of claim 2 , wherein the human has been diagnosed with a biofilm mediated disease. 5. The method of claim 4 , wherein the biofilm mediated disease is bacterial endocarditis and osteomyelitis. 6. The method of claim 4 , further comprising the step of identifying a mammal in need of treatment of the biofilm mediated disease. 7. The method of claim 1 , wherein the mammal has been diagnosed with a need for treatment of the bacterial infection prior to the administering step. 8. The method of claim 1 , further comprising the step of identifying a mammal in need of treatment of the bacterial infection. 9. The method of claim 1 , further comprising administering to the mammal a therapeutically effective amount of at least one antibacterial agent.
Assignees
Inventors
Classifications
Cross-Sectional Technologies · mapped topic
Cross-Sectional Technologies · mapped topic
Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)} · CPC title
Depsipeptides; Derivatives thereof · CPC title
Cross-Sectional Technologies · mapped topic
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10676510B2 cover?
- In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the C1pP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning…
- Who is the assignee on this patent?
- St Jude Childrens Res Hospital
- What technology area does this patent fall under?
- Primary CPC classification C07K11/02. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).